MedPath

PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia

Not Applicable
Completed
Conditions
Febrile Neutropenia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Haematopoietic Stem Cell Transplant, Autologous
Haematopoietic Stem Cell Transplant, Allogeneic
Interventions
Diagnostic Test: Conventional CT
Diagnostic Test: FDG-PET/CT
Registration Number
NCT03429387
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Brief Summary

Patients with acute leukaemia requiring induction or consolidation chemotherapy and those requiring a haematopoietic stem cell transplant are at high risk of fever and infection when they have low white cell counts (neutropenic fever). The causes of neutropenic fever are frequently unknown and patients are treated with broad antibiotics, without a clear target to what is being treated.

This study will prospectively enroll patients who are receiving chemotherapy for acute leukaemia or for a stem cell transplant and compare the diagnostic utility of bacterial and fungal PCR performed directly off blood drawn, to the standard blood culture. Patients who have persistent fever after 72 hours of antibiotics will then be randomized to have either the interventional scan (PET/CT) or the conventional scan (standard CT) to look for a source of infection. Diagnostic yield, change in management and outcomes will be compared between arms.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
147
Inclusion Criteria
  • About to have an allogeneic haematopoietic stem cell transplant, OR
  • About to have an autologous haematopoietic stem cell transplant, OR
  • Commencing induction or consolidation chemotherapy with curative intent for acute myeloid or acute lymphoid leukaemia
Exclusion Criteria
  • Current actively diagnosed infection prior to transplant or chemotherapy
  • Allergy to intravenous contrast for CT imaging
  • eGFR <30
  • Pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional CT armConventional CTParticipants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
FDG-PET/CT armFDG-PET/CTParticipants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
Primary Outcome Measures
NameTimeMethod
Change in management following randomized scanWithin 48 hours of scan result

Defined as:

* referral for targeted sampling, referral for surgery

* change in antimicrobial therapy

* removal of a central line

Secondary Outcome Measures
NameTimeMethod
Proportion of participants with a cause of neutropenic feverBy hospital discharge, an average of 4 weeks

The proportion of participants in each arm where there is a confirmed cause of neutropenic fever

In hospital mortalityBy hospital discharge, an average of 4 weeks

The proportion of patients per arm who have passed away during the admission in which neutropenic fever occurred

Hospital length of stayBy hospital discharge, an average of 4 weeks

The duration (in days) of hospital length of stay for the episode in which neutropenic fever occurred

Proportion admitted to intensive careBy hospital discharge, an average of 4 weeks

The proportion of patients in each arm who were admitted to intensive care during their admission in which neutropenic fever occurred

6 month mortality6 months from study entry

The proportion of patients per arm who have passed away 6 months post study entry

Costs of hospital careBy hospital discharge, an average of 4 weeks

The overall cost of the inpatient stay for the episode in which neutropenic fever occurred

Trial Locations

Locations (2)

Peter MacCallum Cancer Centre

🇦🇺

Melbourne, Victoria, Australia

Melbourne Health

🇦🇺

Parkville, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath